Innate Pharma’s Lacutamab Receives FDA Breakthrough Therapy Designation for Sézary Syndrome
Innate Pharma’s Lacutamab Receives FDA Breakthrough Therapy Designation for Sézary Syndrome Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an innovative anti-KIR3DL2…
Two Dedicated Team Members Awarded the Graeme Rabbits Scholarship
Two Dedicated Team Members Awarded the Graeme Rabbits Scholarship Two deserving individuals are one step closer to achieving their career aspirations in behavioural neuroscience and social work, thanks to receiving $10,000 each toward their tertiary education. The Graeme Rabbits Scholarship,…
Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis
Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis Bristol Myers Squibb (NYSE:BMY) has announced new five-year data from the POETYK PSO long-term extension (LTE) trial, evaluating Sotyktu (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis. The…
Samsung Bioepis Gains EC Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)
Samsung Bioepis Gains EC Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™) Samsung Bioepis Co., Ltd. has announced that the European Commission (EC) has granted marketing authorization for two denosumab biosimilars, OBODENCE™ (60 mg prefilled syringe) and XBRYK™ (120 mg vial), which…
MED-EL USA Gets FDA Approval for SONNET 3 Audio Processor
MED-EL USA Gets FDA Approval for SONNET 3 Audio Processor MED-EL USA has announced the U.S. Food and Drug Administration (FDA) approval of its latest innovation, the SONNET 3 audio processor, designed for use with MED-EL cochlear implants. As the…
FDA Grants Full Approval to Deciphera’s ROMVIMZA™ (vimseltinib) for Symptomatic TGCT
FDA Grants Full Approval to Deciphera’s ROMVIMZA™ (vimseltinib) for Symptomatic TGCT Ono Pharmaceutical Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ROMVIMZA™ (vimseltinib), a kinase inhibitor, for the treatment of adult…
UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response
UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response UroGen Pharma Ltd. (Nasdaq: URGN) announced results from subgroup analyses of the pivotal ENVISION study, assessing the impact of tumor burden and focality on the response to UGN-102,…
IMFINZI® Regimen Boosts Survival in Muscle-Invasive Bladder Cancer: NIAGARA Phase III Post-Hoc Analysis
IMFINZI® Regimen Boosts Survival in Muscle-Invasive Bladder Cancer: NIAGARA Phase III Post-Hoc Analysis A post-hoc exploratory analysis from the Phase III NIAGARA trial has shown that AstraZeneca’s IMFINZI® (durvalumab), when administered perioperatively with neoadjuvant chemotherapy, significantly improves event-free survival (EFS)…
Cancer Breakthroughs: Veracyte’s Decipher Tests and GRID Tool at ASCO GU
Cancer Breakthroughs: Veracyte’s Decipher Tests and GRID Tool at ASCO GU Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) highlight the clinical utility of…
CSL and Arcturus’ KOSTAIVE® Self-amplifying mRNA COVID-19 Vaccine Approved by European Commission
CSL and Arcturus’ KOSTAIVE® Self-amplifying mRNA COVID-19 Vaccine Approved by European Commission CSL (ASX: CSL; USOTC: CSLLY), a global biotechnology leader, and Arcturus Therapeutics (Nasdaq: ARCT), a pioneer in self-amplifying mRNA (sa-mRNA) technology, have announced that the European Commission has…
Galderma’s Nemluvio® (Nemolizumab) EU Approval for Atopic Dermatitis and Prurigo Nodularis
Galderma’s Nemluvio® (Nemolizumab) EU Approval for Atopic Dermatitis and Prurigo Nodularis Galderma announced that the European Commission has granted approval for Nemluvio® (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio, a…
DaVita Inc. Q4 2024 Results
DaVita Inc. Q4 2024 Results DaVita Inc. (NYSE: DVA), a leading provider of dialysis services, has announced its financial and operational results for the fourth quarter and year ended December 31, 2024. Despite facing challenges throughout the year, DaVita achieved…